China Pharma vs Kyntra Bio
CPHI and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CPHI and KYNB compare
China Pharma is the larger company, worth 1.6 times as much as Kyntra Bio ($23.4M against $14.9M).
China Pharma grew revenue faster over the last twelve months (−11.0% versus −37.1% for Kyntra Bio).
Kyntra Bio keeps more of each dollar of sales as profit, with a net margin of 3968% compared with −114% at China Pharma.
Kyntra Bio scores higher on the StockData Score (5 against 4 for China Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CPHI | KYNB |
|---|---|---|
| Size and price | ||
| Market cap | $23.4M | $14.9M |
| Share price | $0.543 | $3.68 |
| Change, 1 year | −64.5% | −66.5% |
| Change, 5 years | −99.8% | −98.8% |
| Beta (5Y) | 0.89 | 1.26 |
| Employees | 221 | 34 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 0.1× |
| P/S | 6.0× | 3.2× (better) |
| P/B | 0.6× | – |
| FCF yield | – | −255% |
| Growth | ||
| Revenue growth (TTM) | −11.0% (better) | −37.1% |
| Revenue growth, 5Y average | −17.5% (better) | −48.4% |
| Profitability | ||
| Gross margin | 11.8% (better) | 6.3% |
| Operating margin | −112% (better) | −1090% |
| Net margin | −114% | 3968% (better) |
| FCF margin | – | −824% |
| Return on equity | −21.0% | – |
| Return on invested capital | −15.5% | – |
| Financial health | ||
| Debt / equity | 0.05 | – |
| Interest coverage | −136.5× | −5.4× (better) |
| Current ratio | 0.26 | 2.69 (better) |
| Altman Z-score | −0.30 (better) | −24.47 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.47% | 24.7% |
| Held by insiders | 0.00% | 15.7% |
| Insider net buying, 12 months | – | $39.7K |
| Short interest, % of float | 0.21% | 2.8% |
Go deeper
- CPHI stock overview
- CPHI income statement
- CPHI valuation and score
- KYNB stock overview
- KYNB income statement
- KYNB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.